Double Bond Pharmaceutical Int. (DBP-B.ST)
- Previous Close
0.2730 - Open
0.2930 - Bid 0.2720 x --
- Ask 0.2840 x --
- Day's Range
0.2730 - 0.2930 - 52 Week Range
0.1600 - 0.7680 - Volume
26,548 - Avg. Volume
108,316 - Market Cap (intraday)
30.35M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases. It offers Temodex/SI-053, a therapy to treat malignant brain tumors; and SA033, a therapy to treat cancers in liver. The company is also developing Belopenem for the treatment of bacterial pneumonia. Double Bond Pharmaceutical International AB (publ) was incorporated in 2014 and is based in Uppsala, Sweden.
www.doublebp.comRecent News: DBP-B.ST
View MorePerformance Overview: DBP-B.ST
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DBP-B.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DBP-B.ST
View MoreValuation Measures
Market Cap
30.64M
Enterprise Value
26.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.13
Price/Book (mrq)
--
Enterprise Value/Revenue
24.47
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-54.40%
Return on Equity (ttm)
-820.98%
Revenue (ttm)
1.09M
Net Income Avi to Common (ttm)
-13.24M
Diluted EPS (ttm)
-0.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
3.99M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.19M